Sosei’s Emergency Contraceptive Effective In Phase III
This article was originally published in PharmAsia News
Executive Summary
Sosei's NorLevo (levonorgestrel) proved effective in Japanese women in a new Phase III trial, the Japanese biopharma said July 10. If approved, the drug would become the first emergency contraceptive available in Japan, the company added
You may also be interested in...
Sosei Group To Revise Strategy And Reduce R&D Expenses
Tokyo-based biopharmaceutical company Sosei Group announced May 14 forecasts for fiscal year 2008 and a review of its strategy. Net sales is estimated to be ¥190 million and income will be at a loss of ¥3.18 billion. In R&D expenses, compared to nearly ¥4 billion in fiscal year 2007, it is estimated to be ¥900 million for FY 2008. Sosei will maintain the rights to NVA237/QVA149 that were in-licensed from Novartis, but will seek to out-license or sell all other assets generated in the U.K. including AD923, a cancer breakthrough pain drug. The company will no longer operate a drug discovery unit but will continue to develop in-house neuropathic pain drug SD118 and emergency contraceptive SHO-175. (Click here for more - Japanese language)
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).